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Objective: To examine variables associated with bone mineral density (BMD) in patients with rheumatoid
arthritis (RA).
Methods:We investigated 373 patients with low to moderately active RA. Patients with low disease activity
were recruited from a cohort of patients in clinical remission. Patients with moderately active disease were
included in a trial comparing the effects of long term high intensity exercise programme and conventional
physical therapy. Demographic and clinical data were collected. Bone mineral density (BMD) was
measured by means of dual x ray absorptiometry (DXA). Associations between demographic and clinical
measurements on the one hand and BMD on the other were investigated in regression analyses.
Results: The patient group consisted of middle aged, mainly female, patients. The median (interquartile
range) disease duration was 7 (4 to 13) years, the mean disease activity score (standard deviation) was
3.2 (1.4). Of the group, 66% was rheumatoid factor positive, and 83% (n =304) had never used
corticosteroids. The median Larsen score of hands and feet was 27 (5 to 61). Greater age and low body
mass index were related to low BMD at the hip and spine. High Larsen score for hands and feet was
significantly associated with low BMD at the hip. The use of corticosteroids was not independently
associated with BMD. The results of the multiple regression analyses also applied to the subgroup of
corticosteroid naive patients.
Conclusion: BMD data of patients with low to moderately active RA demonstrated an association between
high radiological RA damage and low BMD at the hip, which suggests an association between the severity
of RA and the risk of generalised bone loss, which also occurred in corticosteroid naive patients.
G
eneralised osteoporosis is an extra-articular complica-
tion of rheumatoid arthritis (RA).1 Decreased bone
mineral density (BMD) 2 3 plus an increased risk
of both hip and vertebral fractures in patients with RA
compared with patients without RA has been demonstrated
in several studies.4–6
Previous studies helped to unravel the extent of osteo-
porosis and change in BMD in patients with RA. The
occurrence of osteoporosis in these studies is 15–20% at the
hip and the spine.7 8 Haugeberg elegantly showed a twofold
increase in osteoporosis in women with RA and a twofold
increase of reduced bone mass in men with RA, compared
with patients without RA in a population based study.8 9
Numerous studies have investigated the relation between
demographic and disease related variables on the one hand,
and bone mass on the other, in patients with RA. These
studies tried to identify patients at high risk of osteoporo-
sis.10–12 Studies investigating the variables associated with
BMD13–16 showed some inconsistencies, which might be
caused by differences in methodological aspects, such as
sample size and patient selection. Moreover, the complex
interaction between inflammation, immobility, and corticos-
teroid use may contribute to the lack of unanimous results.
Our hypothesis was that disease related variables such as
disease duration and physical disability contribute to BMD
loss. In particular, we intended to confirm the association
between cumulative disease activity (expressed as radiologi-
cal damage) and low BMD7 17 in 373 outpatient clinic based
patients, including a subgroup of 304 corticosteroid naive
patients. In contrast to Sambrook, we assessed the radi-
ological damage of the hands as well as the feet.17 Compared
with the two previous investigations, the present cross
sectional study investigates a larger number of patients,
including many corticosteroid naive patients, with shorter
disease duration.7 17
METHODS
Patients
All patients included fulfilled the American College of
Rheumatology (ACR) 1987 revised classification criteria for
RA.18 In general, these patients with RA had a low to
moderately active disease. Patients were participating in one
of two research projects; the RAPIT trial (n=300)19 and a
cohort of patients in clinical remission (n=76).20 The RAPIT
study was a 2 year multicentre randomised clinical trial.19
The patients included in this trial were between 20 and
70 years old and with ACR functional class I–III.21 Patients
were included if they were on a stable regimen of disease
modifying antirheumatic drugs (DMARDs) in the 3 months
prior to inclusion and able to exercise on a bicycle. Patients
suffering from a serious cardiovascular and/or pulmonary
disease contraindicating intensive exercise, and patients with
a prosthesis of a weightbearing joint were excluded. The
second project concerned a cohort of patients in clinical
remission.20 At inclusion in the cohort, the patients fulfilled
Abbreviations: ACR, American College of Rheumatology; BMD, bone
mineral density; BMI, body mass index; DAS, disease activity score;
DMARD, disease modifying antirheumatic drug; DXA, dual x ray
absorptiometry; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid
factor
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Pinal’s modified criteria of clinical remission.22 Retros-
pectively, patients had non-active RA during 6 months before
inclusion in the cohort, and patients were excluded from
participation in the remission cohort if they were using
corticosteroids at the time of inclusion.
In the current study, we investigated baseline data of 300
RAPIT patients and data from 3 years after inclusion in the
cohort of patients in clinical remission. Therefore, a small
number of the patients from the remission cohort were
reported as current users of corticosteroids. Of the 187
patients originally participating in the remission cohort, 76
were available for the current study. The patients from the
remission cohort were selected based on persistent remission
and willingness to participate in the present study. Three
patients participated in both the RAPIT trial and the
remission cohort. The data of these three patients were
counted in the remission cohort group. At the time of clinical
examination, all patients underwent a BMD measurement,
unless (in case of the remission cohort) they had had a BMD
measurement within the previous year.
Demographic and clinical variables
The demographic and clinical variables of the patients were
systematically retrieved by interview and clinical examina-
tion. The demographic variables collected were age, body
weight, height, and disease duration. Other data collected
concerned menopause status, smoking status, use of anti-
osteoporotic drugs and DMARDs, and history of corticoster-
oid use. Three corticosteroid variables were investigated
(current use (yes or no), previous use (yes or no), and never
versus ever use). Owing to the small number of current users,
never versus ever use was chosen as the corticosteroid
variable in the multiple regression. The fracture history of the
patient (fracture after 25 years of age) and their first degree
relatives (fracture after 50 years of age not caused by accident
involving motorised traffic) was also recorded.
RA disease activity core measures were collected: pain;
patient’s and investigator’s global disease activity assessment
measured on a visual analogue scale (0–100 mm); physical
disability by means of the Health Assessment Questionnaire
(HAQ),23 Ritchie score; 44 swollen joint count; and the acute
phase reactant (erythrocyte sedimentation rate; ESR). The
disease activity score (DAS) was calculated.24
The radiological damage to the joints of the hands and feet
was assessed by a trained rheumatologist according to the
Scott modification of the Larsen method.25 As a further
modification, the wrists were evaluated as a single unit and
the score of each wrist was multiplied by 5. The intra-
observer variability was calculated by means of the intraclass
correlation coefficient (ICC=0.97) and Cronbach’s a (0.99)
on a sample of 15 randomly chosen x rays.
BMD measurements
BMD measurements of the hip (femoral neck) and lumbar
spine L1–4 in anteroposterior view were carried out by
trained technicians at each centre. Several quality aspects of
the BMD data collected on the four different dual energy x
ray absorptiometry (DXA) machines were examined. In vitro
reproducibility, expressed as a coefficient of variation (CV),
was 0.8%, 0.3%, 0.3%, and 1.3% using the Hologic 2000, two
Hologic 4500 machines, and the Lunar DPX, respectively. At
the femoral neck, the corresponding figures were 3.7%, 2.6%,
2.6%, and 2.3%.
To prevent systematic error of the BMD caused by the use
of different DXA machines, we performed cross calibration of
the four different DXA machines. The centre where the BMD
of the majority of the patients was measured was chosen as
the reference centre. The raw BMD values of the reference
centre and the adjusted BMD values of the other centres were
compared with the Hologic (L1–4) and NHANES (femoral
neck) reference populations for T and Z score estimation.
Ethics
The study protocols of the original research projects and the
current study were approved by the medical ethical commit-
tees at the respective centres.
Statistical analysis
Data of all patients as well as subgroups of men and women
separately, corticosteroid naive patients, and patients with
radiological damage (Larsen score.0), were analysed. The
independent variables associated with BMD at different
measurement sites were investigated by means of linear
regression. In the crude analysis, relations between demo-
graphic and clinical variables listed in table 1 and BMD were
investigated. Based on the results of the corresponding crude
analysis (p,0.20) and presumed clinical relevance, variables
were added to the respective multiple regression models. In
all multiple regression models, we adjusted for participa-
tion in original study protocol (RAPIT or remission), thus
controlling for the heterogeneity between the respective
original patient groups. The models for the total patient
group were then further refined by tentatively adding first
order interactions, squared terms investigating curve of the
regression, and single variables initially excluded from the
model based on the results of the crude analysis. A two sided
p value of(0.05 was considered statistically significant.
RESULTS
Demographic and clinical characteristics
The demographic and clinical characteristics of the 373
patients included in the study are shown in table 1. The
patient group consisted of middle aged, mainly female,
patients with RA. Most of the women were postmenopausal.
The patients had a moderate disease duration and a low
disease activity. Most of the patients were rheumatoid
factor (RF) positive and had little radiological damage. The
demographic and clinical variables of the patients per sub-
group, based on original study, differed in accordance with
the inclusion criteria of the respective study protocols. The
patients from the remission cohort were older, had a longer
disease duration, a lower DAS at clinical examination, a more
favourable distribution of the ACR functional classes, and
less current corticosteroid use, compared with the patients
participating in the RAPIT trial. There was a tendency
towards less RA damage, as expressed by HAQ and Larsen
score, in the remission cohort patients. Although several
demographic and clinical characteristics had missing values,
there was no difference in hip and spine BMD between
patients in whom the respective characteristics were present
or absent (data not shown).
BMD, frequency of osteoporosis, and reduced bone
mass
The frequencies of osteoporosis (T score (22.5 SD)26 and
reduced bone mass (Z score (21 SD), according to sub-
group and BMD measurement site, are presented in table 2.
In the total patient group, osteoporosis occurred in 6.5% and
12.6% in the femoral neck and spine, respectively. Reduced
bone mass occurred in 18.9% in the femoral neck and in
20.7% in the spine (all patients). In all (sub)groups pre-
sented, the group of premenopausal women excepted, osteo-
porosis occurred more frequently in the spine compared
with the hip. In two patients from the remission cohort, no
hip measurement was performed owing to bilateral hip
replacement.
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Variables associated with BMD in all patients
The demographic and disease related variables listed in table 1
were investigated in a crude single regression analysis with
BMD. In the crude analysis, the following variables were
associated with BMD at both the lumbar spine and the
femoral neck (p,0.20): age, body mass index (BMI), meno-
pause, age at menopause, disease duration, ESR, ever use of
DMARDs, use of bisphos-phonates, use of anti-osteoporotic
drugs, Larsen score of hands and feet, fractures in first degree
relative, and fractures at .25 years of age. In addition, sex
was associated with BMD in the lumbar spine and the
number of swollen joints was associated with BMD in the
femoral neck.
The variables finally investigated as independent variables
associated with BMD in the total group of patients are shown
in table 3. Greater age and lower BMI were independently
associated with low BMD in both the femoral neck and spine.
Sex was also significantly associated with both hip and spine
BMD. Participation in the RAPIT trial and high total Larsen
score were associated with low BMD in the hip. None of the
corticosteroid variables was significantly related to BMD in
either the hip or the spine. The confidence intervals of the b
coefficient of corticosteroid use (never versus ever) just
exceeded zero in the positive direction, suggesting a lack of
power in demonstrating an association between corticoster-
oid use and low BMD. The association between age and BMD
Table 1 Demographic variables, disease related and therapy variables, damage, bone
mineral density, and fractures
All patients RAPIT Remission
(n = 373) (n = 297) (n = 76)
Demographic variables
Age (years) 53.8 (11.9) 52.0 (11.1) 60.9 (12.3)
Sex (women/men) (%) 77/23 79/21 68/32
BMI (kg/m2) 26.4 (4.8) 26.7 (5.0) 25.3 (3.5)
Menopause (%) 63.5 60.7 75.0
Menopause age (years) 46.8 (5.3) 46.8 (5.0) 46.9 (6.6)
Current smoker (%) 24.6 23.8 27.6
Disease variables
Disease duration (years) 7.0 (4.0 to 13.0) 6.0 (3.0 to 12.0) 9.0 (6.0 to 18.0)
Rheumatoid factor positive (%) 66 72 43
Investigator’s global assessment (VAS
0–100 mm)
20.0 (7.0 to 34.8) 24.0 (10.0 to 37.5) 12.0 (3.0 to 19.0)
Pain (VAS 0–100 mm) 30.0 (10.0 to 54.0) 32.0 (13.0 to 57.0) 14.0 (4.8 to 37.0)
Disease activity (VAS 0–100 mm) 27.0 (10.0 to 51.0) 32.0 (13.0 to 52.5) 16.0 (4.0 to 29.5)
HAQ (range 0–3) 0.6 (0.3 to 1.0) 0.6 (0.3 to 1.0) 0.5 (0.0 to 1.1)
Ritchie score 2 (2 to 13) 8 (4 to 14) 2 (0 to 5)
44 swollen joint count 10 (5 to 16) 12 (6 to 18) 4 (2 to 8)
ESR (mm/1st hour) 15.0 (8.0 to 27.0) 17.0 (8.0 to 29.0) 11.0 (5.0 to 22.0)
DAS 3.2 (1.4) 3.5 (1.3) 2.0 (1.1)
ACR functional class (I/II/III) (%) 31.4/40.2/28.4 18.2/48.5/33.3 82.9/7.9/9.2
Therapy variables
Corticosteroids (%)
Never user 82.8 84.2 71.1
Previous user 9.3 4.7 26.3
Current user 7.9 9.1 2.6
Ever user of DMARDs (%) 95.6 96.2 93.4
Current user of HRT (%) 3.8 2.2 9.6
Current user of bisphophonates (%) 3.0 2.4 5.3
Current user of anti-osteoporotic drugs (%) 12.5 9.5 22.4
Damage variable
Larsen score hands and feet (0–200) 27.0 (5.0 to 61.0) 31.0 (5.5 to 62.5) 15.0 (2.0 to 51.0)
BMD variables
BMD femoral neck (g/cm2) 0.78 (0.13) 0.78 (0.13) 0.80 (0.14)
BMD spine L1–4 (g/cm2) 0.99 (0.16) 1.00 (0.16) 0.98 (0.16)
Z score femoral neck 20.06 (1.08) 0.09 (1.04) 20.64 (1.06)
Z score spine L1–4 0.59 (1.88) 1.01 (1.79) 21.07 (1.23)
T score femoral neck 20.76 (1.15) 20.78 (1.17) 20.67 (1.04)
T score spine L1–4 20.87 (1.40) 20.82 (1.42) 21.07 (1.34)
Fractures
Fracture 1st degree relative (%) 15.3 15.9 13.2
Fracture patient.age 25 (%) 18.2 16.7 23.7
Mean (SD) for continuous variables with normal distribution. Median (IQR) for continuous variables with non-
normal distribution. ACR, American College of Rheumatology; BMD, bone mineral density; BMI, body mass index;
DAS, disease activity score; DMARD, disease modifying anti rheumatic drug; ESR, erythrocyte sedimentation rate;
HAQ, health assessment questionnaire; HRT, hormone replacement therapy; anti-osteoporotic drugs, hormone
replacement therapy, bisphosphonates, calcium, and/or vitamin D supplementation; VAS, visual analogue scale.
Table 2 Frequency of osteoporosis and reduced bone
mass in hip (femoral neck) and spine, L1–4 among all
patients with RA and the respective subgroups according
to sex, menopausal state, and original study in which they
participated (%)
Osteoporosis* Reduced bone mass
Femoral
neck
Spine
L1–4
Femoral
neck
Spine
L1–4
All (n = 373) 6.5 12.6 18.9 20.7
Men (n = 87) 3.5 8.0 23.3 40.2
Women
All women (n = 286)` 7.4 14.0 17.6 14.7
Premenopausal (n = 96) 3.1 3.1 22.9 17.7
Postmenopausal (n = 167) 10.3 21.7 16.4 13.3
RAPIT (n = 297) 7.1 12.1 15.2 13.8
Remission (n = 76) 4.1 14.7 34.2 48.0
*T score (22.5 SD; Z score (21 SD; `Owing to missing values the
total differs from the sum of subgroups of women.
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was different for men and women; the interaction term of
age and sex contributed significantly to the final regression
models of hip and spine. From the b coefficients presented
in table 3, it was calculated that with increasing age, BMD
in women decreases more than in men. For example, the
BMD in women decreased 0.005 g/cm2 per year in this
model, whereas in men the decrease was 0.001 g/cm2 per
year. Consequently, at 50 years of age, men had 0.02 g/cm2
more bone than women. At 70 years of age the difference
increased: men had 0.10 g/cm2 more bone than women. The
final model for hip BMD explained 22% of the variation in
BMD; for the spine model this percentage was 17%. None of
the squared terms contributed significantly to the model. A
number of other variables, including age, smoking status,
disease duration, RF status, DAS, HAQ, and ESR, did not
show an independent association with BMD in the multi-
variate analysis.
Variables associated with BMD in subgroups of
patients
Multivariate analyses of men and women separately showed
results in line with the results for the total patient group
(data not shown). The final model found for the total patient
group was applied to these subgroups, with sex omitted as a
variable from the two respective subgroup analyses. Duration
of menopause was added to the analysis of the subgroup of
women. In women, longer duration of menopause and lower
BMI were associated with low BMD at both hip and spine. At
the hip, participation in the RAPIT trial and joint damage as
expressed by the Larsen score were also independently
associated with low BMD. The percentage of variance
explained (R2) was 31% for the femoral neck model and
30% for the spine model. In men, participation in the RAPIT
trial was the only variable significantly associated with low
BMD at the hip and the spine. At the femoral neck, low BMI
was associated with low BMD. The R2 of the models were
17% and 11% at the femoral neck and spine, respectively.
The subgroup analysis of the corticosteroid naive patients
also showed results in line with the results for the total
patient group (data not shown). The same variables were
independently associated with BMD at both measurement
sites. At the hip, the R2 of the model increased from 22% to
24%, whereas at the lumbar spine, the R2 of the model
remained 17%. None of the added squared terms and initially
excluded single variables (including age, smoking status,
disease duration, RF status, DAS, HAQ, and ESR) contributed
significantly to the model.
Finally, we investigated the association between radio-
logical damage and BMD in a subgroup of 308 patients with
radiological damage (Larsen score.0), in an attempt to
improve the power of the data (data not shown). The final
model found for the total patient group was applied to the 308
patients. The only marked difference from the results of the
total patient group was that ever use of corticosteroids was
now independently associated with a lower BMD at the
lumbar spine (b=–0.0467, p=0.04). The R2 of the models
changed to 20% and 19% for the femoral neck and spine,
respectively.
DISCUSSION
The present study confirmed the hypothethetical association
between a high Larsen score and low BMD in the femoral neck
in a large sample of patients with RA with low to moderately
active disease. Moreover, the well known associates of high
age and low BMI were independent variables associated with
low BMD at all measurement sites. With increasing age, BMD
decreased more in women than in men im both the hip and
the spine. The current results were confirmed in a large
subgroup of corticosteroid naı¨ve patients. This is interesting as
these associations had not been studied previously in a large
group of corticosteroid naive patients.7 17
Previous studies7 17 showed an inverse association between
joint damage, expressed by the Larsen score, and BMD mea-
sured by DXA in patients with a disease duration of more than
10 years in relatively small patient groups. With the present
study, we confirmed these findings in a large population that
was heterogeneous for disease duration and joint damage. The
repeatedly observed association between severe joint damage
and low BMD suggests an association between cumulative
disease activity and low BMD, because the Larsen score, in our
view, appears to be an appropriate measure of past fluctuating
disease activity in cross sectional studies on BMD in RA. An
alternative explanation of the association between severe joint
damage and low BMD might be that joint damage contributes
to physical inactivity with subsequent decrease in muscle
strength, and thereby leads to less loading of the bone,
resulting in low BMD. However, approaching this alternative
explanation by adding physical disability, as expressed by the
HAQ score, to the final regression models did not show an
independent effect of HAQ on BMD.
The absence of a significant association between Larsen
score and BMD of the spine in our population could be
ascribed to osteoarthritis of the spine, atherosclerosis of the
aorta, and vertebral deformities, which increase the mea-
sured BMD and thus obscure a possible relation between
potential predictors and ‘true’ BMD. The same mechanism
might explain the lower percentage of variance explained by
the final model of spine BMD compared with hip BMD.
Because of the difficult interpretation of a spine BMD mea-
surement, recent recommendations prefer the measurement
Table 3 Multiple linear regression analysis of BMD (g/cm2) at different sites of
measurement (dependent variable), demographic and disease variables (independent
variables)
Femoral neck Spine L1–4
b SE 95% CI b SE 95% CI
Original study 20.061 0.017 20.095 to 20.027` 20.007 0.021 20.049 to 0.035
Sex 20.18 0.084 20.34 to 20.0161 20.41 0.10 20.61 to 20.21`
Age (years) 20.005 0.001 20.006 to 20.004` 20.006 0.001 20.007 to 20.004`
Interaction (age6 sex) 0.004 0.001 0.001 to 0.007` 0.008 0.002 0.005 to 0.012`
BMI (kg/m2) 0.006 0.001 0.004 to 0.009` 0.005 0.002 0.002 to 0.009`
Corticosteroid use 20.028 0.023 20.062 to 0.007 20.038 0.021 20.080 to 0.005
Larsen score: hands
and feet
20.0004 ,0.001 20.001 to 0.000` 20.0002 ,0.001 20.001 to 0.000
R2 22 17
BMD, bone mineral density; SE, standard error; CI, confidence interval; BMI, body mass index; R2, percentage of
total variance explained in the model. Numbers needed for regression equation: original study: 1 = remission
cohort, 2 = RAPIT trial; sex: 0 =women, 1 =men; corticosteroid use: 0 = never, 1 = ever. 1P,0.05; `P,0.01.
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of BMD in the hip to other sites.27 Furthermore, the low
percentage of explained variance of the final regression
models might have been caused by the selection of patients
with low to moderate disease activity.
Some previous reports did find an association between
corticosteroid use and low BMD,16 28 whereas others,13 29
including our main analyses, did not. There are several
explanations for the lack of a significant association between
corticosteroid use and low hip or spine BMD in the main
multivariate analyses in our study; firstly, the low number of
corticosteroid users among the patients and secondly, the
relatively imprecise data collected on corticosteroid use
(never, previous, or current use). Both explanations yield a
lack of power to discriminate an existing negative association
(table 3) between corticosteroid use and BMD. The subgroup
analysis of patients with radiological joint damage was an
attempt to increase the discriminatory power, and showed a
significant negative association between previous corticoster-
oid use and low BMD at the lumbar spine, thus apparently
confirming these explanations.
RF status, disease duration, and HAQ score, variables
related to BMD in other studies,2 8 13 did not independently
predict low BMD in the present study. An explanation for the
divergent findings may be the incorporation of the (effects
of) RF status, disease duration, and HAQ score on the Larsen
score, a variable not investigated in the aforementioned
studies.
The association between joint damage and low BMD found
in (corticosteroid naive) patients with RA suggests that some
of the pathophysiological processes involved in generalised
osteoporosis appear to be common to those for local bone loss
consisting of juxta-articular osteoporosis and bone erosions
of individual joints. If cytokines, for instance tumour necrosis
factor a (TNFa), are involved in the development of general-
ised osteoporosis, treatment with anti-TNFa should not only
reduce disease activity and joint damage in RA but also
prevent or slow down the development of generalised bone
loss.
All eligible patients attending the outpatient clinic were
consecutively enrolled in the respective original studies. Due
to the inclusion and exclusion criteria applied, the two
patient samples might not be representative of the respective
clinic populations. Notwithstanding the limitations regarding
representation, the large sample studied, which contains
premenopausal women, postmenopausal women, and men,
with heterogeneous disease duration and joint damage,
yields interesting results.
In summary, the consistent findings of a relationship
between high cumulative disease activity and low BMD
suggest an association between the severity of RA and the
risk of generalised bone loss.
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